Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicines

Affiliations

• ¹ Sanofi, Cambridge, MA, USA. richbrennan@gmail.com.
• ² Pfizer, La Jolla, CA, USA.
• ³ Metrion Biosciences, San Diego, CA, USA.
• ⁴ GSK, Stevenage, UK.
• ⁵ UCB Biopharma, Braine-l'Alleud, Belgium.
• ⁶ Novartis Biomedical Research, Basel, Switzerland.
• ⁷ Vertex Pharmaceuticals, Boston, MA, USA.
• ⁸ GSK, Waltham, MA, USA.
• ⁹ Janssen Research & Development, San Diego, CA, USA.
• ¹⁰ Neurocrine Biosciences, San Diego, CA, USA.
• ¹¹ AstraZeneca, Cambridge, UK.
• ¹² Grunenthal, Berkshire, UK.
• ¹³ Sanofi, Frankfurt, Germany.
• ¹⁴ Novartis Biomedical Research, Cambridge, MA, USA.
• ¹⁵ Blueprint Medicines, Cambridge, MA, USA.
• ¹⁶ Takeda Pharmaceuticals, Cambridge, MA, USA.
• ¹⁷ Armstrong Pharmacology, Macclesfield, UK.
• ¹⁸ Merck, North Wales, PA, USA.
• ¹⁹ AbbVie, North Chicago, IL, USA.
• ²⁰ Alexion Pharmaceuticals, Wilmington, DE, USA.
• ²¹ Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.
• ²² Faegre Drinker Biddle and Reath, LLP, Washington, DC, USA.